A Phase 1 interventional study of [14C] D-2570 group in Mass Balance Study, sponsored by InventisBio Co., Ltd. Active, not recruiting at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by InventisBio Co., Ltd · Phase 1, Interventional, and Basic science
Radiolabeled drug substance balance clinical studies are commonly used methods to elucidate the metabolic and excretion characteristics of drugs in the human body. They are widely applied in the research and development of innovative drugs both domestically and internationally, and their safety has been validated through extensive human trials. The primary objectives of this study are as follows:
To quantitatively analyze the total radioactive activity (TRA) in urine and feces, thereby determining the radioactive recovery rate in humans and identifying the primary excretion pathways. To obtain radioactive metabolite profiles in human plasma, urine, and feces, identify the major metabolites, and determine the principal metabolic and elimination pathways. To quantitatively analyze the total radioactive activity in whole blood and plasma, derive the pharmacokinetic parameters for total radioactivity in plasma and whole blood (if applicable), and investigate the distribution of total radioactivity between whole blood and plasma.
InventisBio Co., Ltd is the lead sponsor of 32 studies on the registry; 10 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: [14C] D-2570 group
\[14C\] labeled D-2570
Percentage of unchanged drug and its metabolites in plasma, urine and feces to the administered dose
Time frame: 2 weeks
Total recovery in excrement (the ratio of the radioactivity in excrement samples to the radioactivity of the administered drug)
Time frame: 2 weeks
Total Radioactivity of D-2570 in Plasma and Whole Blood
Time frame: baseline to 2 weeks
Whole blood/plasma ratio for TRA (total radioactivity) at different time points
Time frame: Baseline to 2 weeks
Incidence and severity of AEs based on NCI CTCAE V6.0
Time frame: Baseline to 3 weeks
Blood concentration of D-2570
Time frame: Baseline to 2 weeks
Blood concentration of D-2570 metabolites (if applicable)
Time frame: Baseline to 2 weeks
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
InventisBio Co., Ltd